


Researchers discover potential treatments for common complication following bone marrow transplant

February 14 2024



Kinase binding activity analysis using DiscoverX Kinomescan profiling. 1.1-1.4: Off-target kinase activities were assessed using the commercially available screen from Eurofins. All four test compounds were tested at a high concentration (1 uM) to maximize the sensitivity of the screen. The DiscoverX Kinomescan utilizes an active site-directed competition assay to measure the binding activity of test compounds to 450 human kinases. The assay does not

PCYC-274



utilize ATP and is thus not a functional kinase activity screen. 1.5-1.6: After animals in allogeneic groups were dosed with various test compounds at their indicated dose regimens, spleen, and thymus tissue samples were harvested 4 h after the final dose to determine BTK and ITK occupancy levels due to drugtarget engagement. Occupancy was determined in the spleen for BTK and thymus for ITK using selective irreversible probes for each target using an ELISA format with MSD detection (see Methods for details). Error bars are shown as SEM. P value 0.01 to 0.05 = *, P value 0.001 to 0.01 = ***, P value 0.001 to 0.001 = ***, P value

Citation: Researchers discover potential treatments for common complication following bone marrow transplant (2024, February 14) retrieved 13 May 2024 from https://medicalxpress.com/news/2024-02-potential-treatments-common-complication-bone.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.